Intercure

Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. The products are distributed to hospitals, pharmacies, research, and government organizations. The company has two segments namely: Cannabis segment and Biomed segment, out of which it derives maximum revenue from Cannabis segment.

AI-Generated Image

Analyst Color

Cannabis

News

Markets

Analyst Ratings

Trading Ideas

INCR

InterCure Ltd. has shown resilience in its H1 2024 performance despite facing significant challenges according to research by Z&amp;A.

Are Investors Missing The Forest? 35% Stock Drop Masks The International Potential Of This Weed Company

cannabis earnings, money marijuana Cannabis,Plant,On,Coins,Stack.marijuana,Growing,Business,Concept.

Earnings

Top Seller Of Pharmaceutical Cannabis Outside US Grew By Double-Digits, Focuses On Germany

AI Generated Image 

Government

Regulations

Small Cap

IPOs

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

IMCC

TCNNF

Some European cannabis companies are already planning initial public offerings (IPOs) on the Nasdaq, encouraged by the prospect of a less restrictive regulatory environment. The potential rescheduling of cannabis to Schedule III of the Controlled Substances Act and Germany’s recent decriminalization have ignited optimism within the sector.

European Cannabis Companies Race To The Nasdaq: $1B In Tax Break On The Horizon

Intercure Ltd

Press Releases

InterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 million

InterCure to Participate in Canaccord Genuity's 8th Annual Global Cannabis Conference

InterCure Announces Expansion of its Strategic partnership with Cookies to Germany

InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million

Market Insight: Power Struggle Arises at XTL Biopharmaceuticals: Court Documents Reveal 'The Social Proxy' Founders Fear Collapse Amidst Refusal for Cash Infusion (NASDAQ: XTLB)

InterCure has Secured Funding of NIS 66M to support the recovery of Nir Oz Facility

InterCure Names Alexander Rabinovich as Chairman Replacing Ehud Barak

XTLB

TD Cowen

Comments

Intercure

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga